Search Results - alzheimer%e2%80%99s+disease

10 Results

Sort By:

Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis

Summary: The NIA seeks co-development partners and/or licensees for the further development of Cα-peptide as a therapeutic that inhibits islet amyloidosis. Description of Technology: Over 32 million Americans are living with Diabetes and newly diagnosed cases of type 1 and type 2 diabetes is increasing. A defining feature of type 2 diabetes...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Qing Rong Liu, Min Zhu, Pingbo Zhang, Josephine Earley, Luigi Ferrucci

Keywords(s): Alzheimer’s Disease, Amyloidosis, C-peptide, DIABETES, Egan, insulin, Islet Amyloid Polypeptide, Liu, National Institute on Aging, NIA

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Endocrinology

Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease

Summary: The NIA seeks co-development partners and/or licensees for the further pre-clinical and clinical development of TTI-101, hydroxychloroquine, and Dasatinib to treat Alzheimer’s disease. Description of Technology: There are no effective treatments for Alzheimer’s disease (AD), a progressive brain disease that slowly destroys a...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Madhav Thambisetty

Keywords(s): Alzheimer’s Disease, ApoE, Apolipoprotein-E, Aβ, FYN, National Institute on Aging, Neuroinflammation, NIA, STAT3, Tau Phosphorylation, Thambisetty, YES1

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Neurology, Collaboration Sought > Licensing

Tamperless Tensor Elastography Imaging

Summary: The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of tamper-less tensor elastography imaging in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Peter Basser, Magdoom Mohamed Kulam Najmudeen

Keywords(s): Alzheimer’s Disease, Anisotropy, Basse, brain, CANCER, Elasticity Tensor, Elastography, Eunice Kennedy Shriver National Institute of Child Health an, Magnetic Resonance Imaging, MRI, Najmudeen, NICHD, TBI, TRAUMA, Traumatic Brain Injury

Category(s): TherapeuticArea > Neurology, Application > Diagnostics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation

Description of Technology: Over 34 million Americans are living with diabetes. An estimated 6.5 million Americans are living with Alzheimer’s disease (AD) and type 2 diabetes mellites (T2DM). Amyloidosis due to aggregation of amyloid-β is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP37) in human...

Published: 4/16/2026 | Updated: 8/2/2023 | Inventor(s): Qing Rong Liu, Min Zhu, Josephine Earley

Keywords(s): Ad, Age-Associated Disease, Alzheimer’s Disease, Amyloidosis, Amyloids, Biomarkers, DIABETES, IAPP, Islet Amyloid Polypeptide Isoforms, Liu, National Institute on Aging, NIA, PEPTIDYL

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease

Summary: The NICHD is seeking licensees for development of Carboxypeptidase E (CPE) as a therapy for MCI or AD. Description of Technology: There is no known cure for Alzheimer’s disease, a brain disorder that severely affects memory, thinking, learning, and organizing skills. It eventually decreases a person’s ability to carry out simple,...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Yoke Peng Loh, Yong Cheng

Keywords(s): “Cognitive impairment”, Ad, Alzheimer’s Disease, BNDF, brain, Brain-Derived Neurotrophic Factor, Carboxypeptidase E, CPE, Hippocampus, LOH, MCI, MEMORY, Mild Cognitive Impairment, NEURODEGENERATION, NEUROTROPHIC

Category(s): TherapeuticArea > Neurology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

MODULATING BONE MORPHOGENIC PROTEIN (BMP) SIGNALING IN THE TREATMENT OF ALZHEIMER’S DISEASE

MODULATING BONE MORPHOGENIC PROTEIN (BMP) SIGNALING IN THE TREATMENT OF ALZHEIMER’S DISEASE Researchers at Stanford University have described a novel therapeutic target for Alzheimer’s disease. Alzheimer’s disease (AD) presents a large public health burden, effecting an estimated 5.5 million people in the United States and occurring...

Published: 4/13/2023 | Updated: 4/13/2023 | Inventor(s): Michael Clarke, Jane Antony, Maddalena Adorno, Elizabeth Chen, Benedetta n di Robilant, Felicia Reinitz

Keywords(s): Alzheimer’s Disease, BMP, Inhibitor, Neural Progenitor, Stem Cell

Category(s): Technology Classifications > Biology

The preparation of a brain targeted artificial nano-enzyme and application

Reference #: 01514 The University of South Carolina is offering licensing opportunities for The preparation of a brain targeted artificial nano-enzyme and application Background: Chronic neuroinflammation is caused by the activation of microglia, which is the major cause of central neuronal system (CNS) diseases, including Alzheimer’s disease,...

Published: 4/24/2026 | Updated: 6/9/2022 | Inventor(s): Peisheng Xu, Haijun Liu

Keywords(s): Alzheimer’s disease, Amyotrophic lateral sclerosis, brain injury, Brain targeted nanoparticle, Brain tumor, Epilepsy, frontotemporal dementia, glioblastoma, Huntington's disease, Multiple sclerosis, neonatal hypoxic-ischemic, neuroblastoma, Parkinson's disease, post-traumatic stress disorder, Spinal cord injury, stroke

Category(s): Nanotechnology, Health Sciences, Biomedical and Life Sciences

Cell-based Biosensor for Early Alzheimer's Disease Detection

Reference #: 01442 The University of South Carolina is offering licensing opportunities for Cell-based biosensor for early Alzheimer's disease detection Background: Alzheimer’s disease is the 6th leading cause of death in the United States. Early Alzheimer’s disease detection is needed for effective therapy due to the irreversible...

Published: 1/27/2026 | Updated: 3/12/2021 | Inventor(s): Melissa Moss, Brittany Watson

Keywords(s): Alzheimer’s disease, amyloid-beta protein, biomarker, cell-based biosensor, permeability

Category(s): Health Sciences, Biomedical and Life Sciences

Use of fluorescent ANTS to examine the BBB-permeability of polysaccharide

Project ID: D2015-27Invention Description: Methods of generating and administering digestion products of FDA-approved low acyl gellan gum (LA-GAGR) to produce neuroprotective mega-GAGR, midi-GAGR, and mini-GAGR and administration thereof.Applications: Compositions comprising midi and/or mini-GAGR have been shown to be useful for treatment of neurodegenerative...

Published: 8/3/2022 | Updated: 6/17/2015 | Inventor(s): Joshua Park, Kevin Christopher, Vishruti Makani

Keywords(s): ALS, Alzheimer’s disease, Blood-brain Barrier, Brain Trauma, Neuritogenesis, Neurodegenerative, Neuroprotective, Spinal Cord Injury

Category(s):

Novel agents and methods for treating neurodegenerative disorders

Project ID: D2013-69 Midi-GAGR has several desired properties (neurotrophic, anti-oxidant, non-cytotoxic, anti-inflammatory, and BBB-permeable) for treatment of neurodegenerative diseases. Such materials have been shown to cross the blood-brain barrier, reduce the degeneration of cortical, peripheral, and dopaminergic nerve cells under pathogenic...

Published: 4/15/2026 | Updated: 6/17/2015 | Inventor(s): Joshua Park, Dong Shik Kim, Kenneth Hensley

Keywords(s): ALS, Alzheimer’s disease, Blood-brain Barrier, Brain Trauma, Neuritogenesis, Neurodegenerative, Neuroprotective, Spinal, Spinal Cord Injury

Category(s): Neuroscience